Atlas Trials

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

Clinical trial NCT05549661 · RECRUITING

Trial details

NCT number
NCT05549661
Sponsor
Mayo Clinic
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm, Not Otherwise SpecifiedRecurrent Atypical Chronic Myeloid LeukemiaRecurrent Myelodysplastic/Myeloproliferative NeoplasmRefractory Myelodysplastic/Myeloproliferative Neoplasm
Start date
2023-04-04
Primary completion
2027-06-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.